Loading...
Type 2 diabetes is associated with excess risk for kidney stones. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase urine output and alter urine composition in ways that might lower risk for kidney stones. In this U.S. study, researchers compared risks for kidney stones among 600,000 adults with type 2 diabetes who were new users of SGLT-2 inhibitors versus 600,000 propensity score–matched patients who initiated glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which do not have the same renal effects.
During median follow-up of 6 months, risk for kidney stones was significantly lower in patients who began using SGLT-2 inhibitors than in patients who began using GLP-1 receptor agonists…